Reduced CD4+ examinations would provide a significant cost saving: if all stable patients were monitored once per year, the total expenditure would be reduced by 63%, whereas it would be decreased by 50% by monitoring stable patients without HCV annually and those with HCV co-infection twice a year. The gene discussed is CD4; the disease is coinfection.